Companies featured in this edition of the newsletter: ACTC, CUR, CVM, DKAM, ENZ, IMUC, MFGD, NXOI, OMCM, ONEZ, PSID, XSNX

Markets continued to carry momentum during the early stages of last week, as the absence of significant economic news led to a continuation of the upward trend characterizing the past few weeks, until an earnings miss from Dell on Thursday led to a selloff in the technology sector which caused the major indices to end the week mixed. All told, the Dow ended the week in positive territory, gaining 47 points to close at 10318, up 0.5% on the week and 17.6% on the year. The Nasdaq surrendered 1.0% to close at 2146, paring its YTD gains to 36.1%, while the S&P 500 and Russell 2000 lost 0.2% and 0.3% respectively, reducing their yearly gains to 20.8 and 17.1.

Things got off to a strong start on Monday, with the

Companies featured in this edition of the newsletter: ACTC, CVM, CHIP, ENZ, HYTM, IWEB, ONEZ, PHC, SIHI, SRCO

Markets continued their strong performance this week in the absence of any major market driving earnings or economic reports, as the broad based buying that characterized the previous week continued and led to gains in all of the major indices. All told, the Dow added 2.5% on the week, gaining 247 points to close at 10,270, up 17.0% on the year. The Nasdaq posted a 2.6% gain on the week, closing at 2,167 to extend its yearly gains to 37.5%, while the S&P 500 and Russell 2000 gained 2.3% and 1.0% respectively, bringing their yearly gains to 21.1% and 17.4%.

Equity markets carried the momentum from the previous week’s session, as the thin economic calendar and lack of significant earnings reports provided little incentive for investors to slow their buying activities.

Today, BrainStorm Cell Therapeutics Inc. took the opportunity to announce that the company’s therapeutic treatment for neurodegenerative diseases displayed superior results to other current potential stem cell treatments in a recently conducted study.

The Israel Medical Association Journal published a scientific paper, authored by Ofer Sadan, Eldad Melamed and Daniel Offen from Tel Aviv University, showing the migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models of Parkinson’s and Huntington diseases. The study demonstrated that in a rat model for Parkinson’s disease, the efficacy of NTF-SC was superior in behavior, biochemical and histological indices to that of mesenchymal stem cells. The complete study and scientific paper are available on Brainstorm’s website at http://www.brainstorm-cell.com/_Uploads/47Sadan2009.pdf.

Professor Daniel Offen, Brainstorm’s chief scientific advisor, commented, “The results of this study show that the NTF-SC based treatment is efficacious due to NTF secretion and the stem cell’s migratory capabilities. Since our novel technology

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Thursday October 8, 2009, are:

**************************************************************

WYN, Wyndham Worldwide Corporation

WYN provides various hospitality products and services to individual consumers and business customers. WYN’s Lodging segment franchises hotels in the upscale, middle, and economy segments of the lodging industry, as well as provides property management services to owners of these hotels.

Goldman Sachs’s Analyst Steven Kent raised his rating on WYN to “Buy” from “Neutral” and increased his share price target to $26 from $18.

WYN has completed two term securitization transactions involving the issuance of

Vitro Diagnostics Inc. owns various U.S. patents for production of the fertility drug FSH, immortalization of cells, and adult stem cells. The company recently announced the newest addition to its current product lineup, a new serum-free stem cell growth medium.

According to the press release, the new product is a serum-free and animal component-free medium. The product is optimized for human stem-cell growth, and eliminates the risk of exposure to contamination from serum or animal components. Adult stem cells are usually derived from bone marrow, umbilical cord blood, or peripheral blood, which then must be purified to maximize therapeutic benefits. Vitro’s new serum-free stem cell growth medium reduces differentiation and harmful contamination.

Running under the banner, “Harnessing the Power of Cells,” Vitro continues to improve and improve its pipeline of patented adult stem cells and patent-pending technology for stem cell therapy of cancer. Today’s announcement is in line with the company’s

Cytori Therapeutics announced today before the opening bell that the first preclinical study to demonstrate adipose-derived stem and regenerative cells (ADRCs) significantly improved cardiac function after a heart attack has been published. This preclinical study was reported online ahead of print in the International Journal of Cardiology. Funded by Cytori Therapeutics, the study was conducted at Tulane University.

“Treatment of cardiovascular disease, which places one of the greatest burdens on our healthcare system, could be revolutionized by cell therapy,” stated Marc H. Hedrick, M.D., president of Cytori. “We observed a statistically significant improvement in heart function that contributed to our decision to proceed with our APOLLO study. Cardiovascular disease is the most advanced application in Cytori’s product pipeline and could eventually make a substantial contribution to our future commercial activities.”

According to the company, “The APOLLO study is the first clinical trial to investigate uncultured adipose-derived stem and regenerative cells in heart

A.F. analysts clash… can the niche retailer survive the credit crunch?…Crisis begets steadfast citizens… Americans move about the country at lowest rate in 47 years…A long-term outlook on the American stock market…The latest sector to catch Chris Mayer’s attention…U.K. launches historic spending spree, hikes taxes to 50%..

If the credit-strapped suburban mall culture is truly on the rocks, how long do you think this can survive:

Lady Amaranth, Goth Temptress

Among our analysts, a debate brews at the heart of the current consumer conundrum: “Cutting-edge apparel retailer Hot Topic,” writes Wayne Burritt, about the purveyor of goth clothing and lip-piercing paraphernalia, “is loaded with attractive fundamentals and technicals, while its call options offer an oversized premium. Hot Topic is a mall and Web-based specialty retailer that has a proven track record in the often-fickle teen

Vitro Diagnostics Inc., which is doing business as Vitro Biopharma, is committed to harnessing the power of cells. The company owns US patents for the production of the fertility drug – FSH, immortalization of cells, and a pending US patent regarding stem cell-based cancer treatments. Vitro also recently received a Notice of Allowance for its method of generation of adult stem cells.

Vitro announced the introduction of “Tools for Stem Cell and Drug Development” at the recently held Society of Toxicology meeting in Baltimore, MD. These products are designed to support stem cell and cancer research specifically targeting mesenchymal stem cells (MSCs) and a new type of stem cell called induced plurapotent stem cells (iPS). MSCs are adult stem cells that differentiate into several tissue-specific cells, such as collagen, bone and fat cells.

Expanded usage of adult stem cells, such as those provided by Vitro, provides two major benefits. First, use

Pluristem Therapeutics Inc. announced that the US Food & Drug Administration (FDA) has given the company clearance to begin a Phase I clinical trial for the treatment of Critical Limb Ischemia (CLI), the end stage of peripheral artery disease (PAD), using Pluristem’s PLX-PAD. This will be the first clinical trial using PLX-PAD, Pluristem’s placenta-derived stem cells that are expanded using the company’s proprietary 3D PluriX™ technology.

PLX-PAD is a unique one-size-fits-all product that doesn’t require tissue matching before being administered to patients. According to the press release, PLX-PAD will be administered to patients considered “late stage” and defined as patients afflicted with CLI that have not responded to traditional medical or surgical interventions.

Zami Aberman, Chairman, President and CEO of Pluriste, commented, “We are excited the FDA has cleared our IND application for our PLX-PAD product so quickly. PLX-PAD is our first product candidate in our PLX pipeline and this

Pluristem Therapeutics Inc., a bio-therapeutics company focused on the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, announced that its Senior Scientist, Racheli Ofir, Ph.D., has been invited by the Centro di Ricerca E. Menni (CREM), Fondazione Poliambulanza, Brescia, Italy, to present at a workshop titled “Placenta-Derived Cells for Treatment of Inflammatory Diseases: Moving Toward Clinical Applications” on March 13, 2009.

Zami Aberman, Chairman, President and CEO of Pluristem, commented, “The research and medical communities are very interested in the placenta as a superior source for cell therapy. This entire workshop is devoted to studies performed on placental cells and their potential for becoming therapeutic products. At Pluristem, we believe the placenta will play a major role in the developing cell therapy market. Based on substantial pre-clinical data, we have developed a pipeline of placental-derived mesenchymal-like stromal cell products, the first one being PLX-PAD for the